ImmunoPrecise Antibodies Ltd.

Yield per half year: +38.67%
Dividend yield: 0%
Sector: Healthcare

Share chart ImmunoPrecise Antibodies Ltd.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign.

more details
In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Main settings

IPO date 2017-01-03
ISIN CA45257F2008
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета cad
Сайт link
Цена ао 0.5571
Change price per day: +3.75% (0.534)
Change price per week: +13.32% (0.4889)
Change price per month: +20.28% (0.4606)
Change price per 3 month: +55.1% (0.3572)
Change price per half year: +38.67% (0.3995)
Change price per year: -49.64% (1.1)
Change price per 3 year: -89.83% (5.45)
Change price per 5 year: -0.7168% (0.558)
Change price per 10 year: +2 538.1% (0.021)
Change price per year to date: +35.12% (0.41)

Grade

Underestimation
Title Value Grade
P/S 1.84 8
P/BV 1.33 9
P/E 0 0
EV/EBITDA -2.42 0
Total: 5.63
Efficiency
Title Value Grade
ROA, % -39.44 0
ROE, % -59.26 0
Total: 0
Dividends
Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 1.02
Debt
Title Value Grade
Debt/EBITDA -0.5961 10
Total: 9.8
Growth impulse
Title Value Grade
Yield Revenue, % 74.41 8
Yield Ebitda, % 6165.75 10
Yield EPS, % 130.51 10
Total: 9.6

Main owners

Institutions Volume Share, %
Ingalls & Snyder 1 281 305 4.87
Citadel Advisors Llc 75 031 0.29
Northern Trust Corporation 60 914 0.23
Squarepoint Ops LLC 47 957 0.18
Bank of Montreal/Can/ 47 521 0.18
Cibc World Markets, Inc. 41 200 0.16
Gradient Capital Advisors, LLC 26 808 0.1
Renaissance Technologies, LLC 23 000 0.09
Millennium Management LLC 19 011 0.07
Geode Capital Management, LLC 17 484 0.07

Similar companies



Company management

Head Job title Payment Year of birth
Dr. Jennifer Lynne Bath Ph.D. CEO, President & Non-Independent Director 1.02M
Dr. Ilse Roodink Chief Scientific Officer & Interim General Manager of IPA Europe, Oss 277.03k

About company

Address: Canada, Victoria, 3204–4464 Markham Street - Open in google maps, Open in yandex maps
Website: https://www.ipatherapeutics.com